The Mexican government, led by President Claudia Sheinbaum and Secretary of Economy Marcelo Ebrard, announced a collective investment of 10.48 billion pesos by four national pharmaceutical companies as part of the Plan México initiative. The companies involved are Kener, Gembio, Alpharma BiogenTec, and Neolsym. This investment aims to enhance Mexico's pharmaceutical industry by expanding infrastructure, increasing production capacity, and advancing biotechnological development, with a focus on achieving technological self-sufficiency in medicines and vaccines. Notably, Grupo Vazol, which includes Laboratorios Kener and Gen Bio, is investing over 5 billion pesos in expanding the Parque Industrial Toluca 2000. The initiative seeks to strengthen Mexico's autonomy in healthcare and position the country as a reference in the pharmaceutical sector. The government emphasized the importance of this investment to address vulnerabilities highlighted by past health crises such as the COVID-19 pandemic and to support public health through private sector participation.